Sudden Death Trajectories in HFpEF, HFmrEF - Takeaways - MDSpire

Sudden Death Trajectories in HFpEF, HFmrEF

Clinical changes before death overlap across outcomes

  • By

  • Kathryn Wighton

  • March 31, 2026

  • 4 min

Share

  • 1

    Sudden death in HFpEF and HFmrEF patients was preceded by modest worsening in functional status and symptom burden.

  • 2

    In the FINEARTS-HF trial, 215 sudden deaths occurred among 6,001 patients over a median follow-up of 2.7 years.

  • 3

    Patients who experienced sudden death showed slight worsening in NYHA class and increased NT-proBNP levels in the months prior.

  • 4

    Current guidelines do not recommend implantable cardioverter-defibrillators for primary prevention due to risk stratification limitations.

  • 5

    The study's findings suggest that observed trajectories may indicate overall risk rather than specific sudden death prevention.

Original Source(s)

Sudden Death Trajectories in HFpEF, HFmrEF

  • by Kathryn Wighton

  • March 31, 2026

Related Content

Baptist Health Heart & Vascular Care Hosts ECMO Boot Camp for Clinicians

Baptist Health Heart & Vascular Care recently hosted the BHSF–UPMC ECMO Boot Camp at the Education Center at Baptist Health Baptist Hospital.

  • by

  • May 26, 2026

  • 2 min
FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis